Cefotaxime/sulbactam plus gentamicin as a potential carbapenem- and amikacin-sparing first-line combination for neonatal sepsis in high ESBL prevalence settings.

In settings where resistance rates are high, there is an increasing trend to use very broad-spectrum agents such as carbapenems as first-line empirical treatment of neonatal sepsis 6 but this approach risks driving further resistance acquisition.

also in 63,971 other papers